{"id":"NCT00751348","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","officialTitle":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-01","primaryCompletion":"2010-05-27","completion":"2010-05-27","firstPosted":"2008-09-11","resultsPosted":"2017-04-24","lastUpdate":"2018-06-08"},"enrollment":475,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Measles","Varicella","Mumps","Rubella"],"interventions":[{"type":"BIOLOGICAL","name":"PriorixTM","otherNames":[]},{"type":"BIOLOGICAL","name":"VarilrixTM","otherNames":[]},{"type":"BIOLOGICAL","name":"Priorix-TetraÂ®","otherNames":[]}],"arms":[{"label":"PRIORIX-TETRA GROUP","type":"EXPERIMENTAL"},{"label":"PRIORIX + VARILRIX GROUP","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.","primaryOutcome":{"measure":"Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values","timeFrame":"At 42 days post-vaccination","effectByArm":[{"arm":"Priorix-Tetra Group","deltaMin":294,"sd":null},{"arm":"Priorix + Varilrix Group","deltaMin":155,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"},{"comp":"OG000 vs OG001","p":"<0.05"},{"comp":"OG000 vs OG001","p":"<0.05"},{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"11 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":13,"countries":["South Korea"]},"refs":{"pmids":["24427766"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":313},"commonTop":["Fever","Upper respiratory tract infection","Rash","Redness","Nasopharyngitis"]}}